Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 05, 2022 06:00 ET | Source: Opthea Limited

Opthea Data for OPT-302 in Combination with Ranibizumab for Polypoidal Choroidal Vasculopathy (PCV) Presented at ARVO 2022

MELBOURNE, Australia., May 05, 2022 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; Nasdaq: OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and...
April 29, 2022 06:00 ET | Source: Opthea Limited

Opthea Presenting Clinical Data at ARVO 2022 Annual Meeting

MELBOURNE, Australia, April 29, 2022 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; NASDAQ:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and...
April 22, 2022 08:15 ET | Source: Opthea Limited

Opthea strengthens its Board of Directors

MELBOURNE, Australia, April 22, 2022 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; Nasdaq: OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and...
March 10, 2022 06:00 ET | Source: Opthea Limited

Opthea To Present at Oppenheimer’s 32nd Annual Healthcare Conference

MELBOURNE, Australia, March 10, 2022 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive...
March 02, 2022 06:00 ET | Source: Opthea Limited

Opthea Expands Leadership Team with the Appointment of Joel Naor, M.D., M.Sc., MBA as Chief Medical Officer

Key appointment as Opthea progresses the Phase 3 clinical development of OPT-302 in wet AMD MELBOURNE, Australia, March 02, 2022 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; Nasdaq:OPT), a clinical...
February 14, 2022 06:00 ET | Source: Opthea Limited

Opthea Data for OPT-302 in Patients with Polypoidal Choroidal Vasculopathy (PCV) Presented at Angiogenesis 2022

Professor Gemmy Cheung, Singapore Eye Research Institute, presented prespecified subgroup analysis of PCV patients enrolled in Opthea’s Phase 2b clinical trial of OPT-302 in combination with...
February 10, 2022 06:00 ET | Source: Opthea Limited

Opthea To Present at SVB Leerink Global Healthcare Conference

MELBOURNE, Australia, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; Nasdaq:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and...
February 09, 2022 06:00 ET | Source: Opthea Limited

Opthea Announces Presentation at the Angiogenesis, Exudation, and Degeneration 2022 Conference

MELBOURNE, Australia, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; NASDAQ:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and...
January 24, 2022 06:00 ET | Source: Opthea Limited

Opthea Receives A$6.6 m R&D Tax Incentive

MELBOURNE, Australia, Jan. 24, 2022 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; Nasdaq:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and...
January 04, 2022 06:18 ET | Source: Opthea Limited

Opthea To Present at H.C. Wainwright BIOCONNECT Virtual Conference

MELBOURNE, Australia, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive...